| Primary |
| Product Used For Unknown Indication |
59.7% |
| Bronchopulmonary Aspergillosis |
14.9% |
| Aplasia |
6.0% |
| Ill-defined Disorder |
3.0% |
| Induction Of Anaesthesia |
3.0% |
| Prophylaxis |
3.0% |
| Pseudomonas Infection |
3.0% |
| Septic Shock |
3.0% |
| Anaesthesia |
1.5% |
| Antibiotic Prophylaxis |
1.5% |
| Surgery |
1.5% |
|
| Face Oedema |
12.5% |
| Gravitational Oedema |
12.5% |
| Hyperbilirubinaemia |
12.5% |
| Oedema Peripheral |
12.5% |
| Pulse Absent |
12.5% |
| Respiratory Tract Haemorrhage |
12.5% |
| Thrombocytopenia |
12.5% |
| Urogenital Haemorrhage |
12.5% |
|
| Secondary |
| Product Used For Unknown Indication |
33.2% |
| Bronchopulmonary Aspergillosis |
11.9% |
| Drug Use For Unknown Indication |
6.6% |
| Hypertension |
5.8% |
| Prophylaxis |
5.3% |
| Aspergillosis |
4.4% |
| Infection |
4.4% |
| Pain |
3.5% |
| Abscess |
2.7% |
| Acute Myeloid Leukaemia |
2.7% |
| Pruritus |
2.7% |
| Tooth Infection |
2.7% |
| Vulvovaginal Mycotic Infection |
2.7% |
| Urinary Tract Infection |
2.2% |
| Atrial Fibrillation |
1.8% |
| Bronchopneumopathy |
1.8% |
| Toe Amputation |
1.8% |
| Anaesthesia |
1.3% |
| Bronchitis |
1.3% |
| Lung Consolidation |
1.3% |
|
| Cholestasis |
10.0% |
| Drug Interaction |
10.0% |
| Immunosuppressant Drug Level Decreased |
10.0% |
| Renal Failure Acute |
10.0% |
| Drug Hypersensitivity |
5.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.0% |
| Hypersensitivity |
5.0% |
| Impetigo |
5.0% |
| Necrotising Ulcerative Gingivostomatitis |
5.0% |
| Somnolence |
5.0% |
| Tachypnoea |
5.0% |
| Tremor |
5.0% |
| Anaphylactic Shock |
2.5% |
| Anxiety |
2.5% |
| Hepatic Enzyme Increased |
2.5% |
| Hepatitis |
2.5% |
| Hepatocellular Injury |
2.5% |
| Jaundice |
2.5% |
| Maternal Drugs Affecting Foetus |
2.5% |
| Myocardial Infarction |
2.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
18.4% |
| Analgesic Therapy |
13.3% |
| Prophylaxis |
9.6% |
| Product Used For Unknown Indication |
8.3% |
| Diabetes Mellitus |
7.2% |
| Hypertension |
6.4% |
| Breast Cancer |
5.9% |
| Multiple Myeloma |
4.8% |
| Prostate Cancer |
4.0% |
| Pneumonia |
2.9% |
| Immunosuppression |
2.7% |
| Non-small Cell Lung Cancer |
2.7% |
| Pyrexia |
2.4% |
| Metastases To Bone |
2.1% |
| Breast Cancer Recurrent |
1.6% |
| Horner's Syndrome |
1.6% |
| Multiple Sclerosis |
1.6% |
| Otitis Media |
1.6% |
| Renal Transplant |
1.6% |
| Asthma |
1.3% |
|
| Wound Closure |
47.7% |
| Pulmonary Embolism |
6.3% |
| Pneumonia |
5.4% |
| Rectal Haemorrhage |
4.5% |
| Liver Function Test Abnormal |
3.6% |
| Sepsis |
3.6% |
| Sudden Death |
3.6% |
| Thrombophlebitis |
2.7% |
| Viral Infection |
2.7% |
| Appendicitis |
1.8% |
| Death |
1.8% |
| Drug Exposure During Pregnancy |
1.8% |
| Face Oedema |
1.8% |
| Hypersensitivity |
1.8% |
| Nausea |
1.8% |
| Progressive Multifocal Leukoencephalopathy |
1.8% |
| Pulmonary Haemorrhage |
1.8% |
| Respiratory Distress |
1.8% |
| Rhabdomyolysis |
1.8% |
| Spinal Osteoarthritis |
1.8% |
|
| Interacting |
| Product Used For Unknown Indication |
71.4% |
| Muscle Spasticity |
9.5% |
| Prophylaxis |
9.5% |
| Respiratory Tract Infection |
4.8% |
| Sedation |
4.8% |
|
| Haemorrhage |
50.0% |
| Hypertransaminasaemia |
50.0% |
|
